Association of Osteopontin and Cyclooxygenase-2 Expression with Breast Cancer Subtypes and Their Use As Potential Biomarkers

Overview

Journal Oncol Lett

Specialty Oncology

Date 2013 Nov 22

PMID 24260046

Citations 12

Authors

Dhanashri Thorat

Asutosh Sahu

Reeti Behera

Kirti Lohite

Sanjay Deshmukh

Anupama Mane

Swapnil Karnik

Suhaschandra Doke

Gopal C Kundu

Affiliations

Soon will be listed here.

Abstract

Breast cancer is one of the most common malignant tumors among females worldwide and remains a leading cause of cancer-related mortality. Due to the heterogeneous clinical nature of breast cancer, it is necessary to identify new biomarkers that are associated with tumor growth, angiogenesis and metastasis. Osteopontin (OPN) and cyclooxygenase-2 (COX-2) are known to be overexpressed in invasive breast cancer and their overexpression is associated with aggressive histological and clinical features. The present study assessed OPN and COX-2 expression in various subtypes of breast cancer. The expression of OPN and COX-2 was analyzed using immunohistochemistry (IHC) in a cohort of 67 invasive ductal breast carcinoma patients. The statistical analysis was performed using standard statistical software SPSS version 18.0. The associations between OPN and COX-2 and the human epidermal growth factor receptor type 2 (HER2)-overexpressing and non-HER2-overexpressing subtypes were evaluated using the Mann-Whitney U test. The mean OPN level was significantly higher in the HER2-overexpressing subtype compared with the non-HER2-overexpressing subtype. Furthermore, the mean COX-2 expression levels were higher in the HER2-overexpressing subtype compared with the luminal A, luminal B or triple-negative groups. It is well known that carcinomas overexpressing HER2/neu have a worse prognosis than luminal tumors. Hence, it may be hypothesized that an elevated expression of OPN and COX-2 in a HER2-overexpressing subtype may contribute to a more aggressive behavior and be used as diagnostic and prognostic markers in breast cancer.

Citing Articles

Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer.

Niedolistek M, Fudalej M, Sobiborowicz A, Liszcz A, Budzik M, Sobieraj M Arch Med Sci. 2024; 20(2):436-443.

PMID: 38757015 PMC: 11094834. DOI: 10.5114/aoms.2020.93695.

Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway.

Guo M, Liu M, Li W, Wang C, Zhang L, Zhang H J Cancer Res Clin Oncol. 2024; 150(3):155.

PMID: 38526702 PMC: 10963528. DOI: 10.1007/s00432-024-05658-w.

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.

Agresti R, Triulzi T, Sasso M, Ghirelli C, Aiello P, Rybinska I Cells. 2019; 8(2).

PMID: 30791501 PMC: 6406730. DOI: 10.3390/cells8020181.

RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.

Palanissami G, Paul S Horm Cancer. 2018; 9(5):295-325.

PMID: 29987748 PMC: 10355895. DOI: 10.1007/s12672-018-0342-9.

SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling.

Li X, Jiang Z, Li X, Zhang X Onco Targets Ther. 2018; 11:1157-1171.

PMID: 29535539 PMC: 5841350. DOI: 10.2147/OTT.S137146.

References

Shim J, An H, Lee Y, Kim S, Lee K, Lee K . Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol. 2003; 16(12):1199-204. DOI: 10.1097/01.MP.0000097372.73582.CB. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Rudland P, Platt-Higgins A, El-Tanani M, de Silva Rudland S, Barraclough R, Winstanley J . Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002; 62(12):3417-27. View

Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu G . Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets. 2006; 11(1):81-90. DOI: 10.1517/14728222.11.1.81. View

Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P . Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 2011; 15(9):1113-26. DOI: 10.1517/14728222.2011.594438. View

Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H . Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989; 49(11):3104-8. View

Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V . The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006; 6(8):819-30. DOI: 10.2174/156652406779010803. View

Wang Y, Klijn J, Zhang Y, Sieuwerts A, Look M, Yang F . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365(9460):671-9. DOI: 10.1016/S0140-6736(05)17947-1. View

Denkert C, Winzer K, Muller B, Weichert W, Pest S, Kobel M . Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003; 97(12):2978-87. DOI: 10.1002/cncr.11437. View

10.

Glass A, Lacey Jr J, Carreon J, Hoover R . Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007; 99(15):1152-61. DOI: 10.1093/jnci/djm059. View

11.

Chandrasekharan N, Simmons D . The cyclooxygenases. Genome Biol. 2004; 5(9):241. PMC: 522864. DOI: 10.1186/gb-2004-5-9-241. View

12.

Kis B, Snipes J, Isse T, Nagy K, Busija D . Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab. 2003; 23(11):1287-92. DOI: 10.1097/01.WCB.0000090681.07515.81. View

13.

Rangaswami H, Bulbule A, Kundu G . Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16(2):79-87. DOI: 10.1016/j.tcb.2005.12.005. View

14.

Sodek J, Ganss B, McKee M . Osteopontin. Crit Rev Oral Biol Med. 2000; 11(3):279-303. DOI: 10.1177/10454411000110030101. View

15.

Ravdin P, Cronin K, Howlader N, Berg C, Chlebowski R, Feuer E . The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356(16):1670-4. DOI: 10.1056/NEJMsr070105. View

16.

Murthy N, Chaudhry K, Nadayil D, Agarwal U, Saxena S . Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer. 2009; 46(1):73-4. DOI: 10.4103/0019-509x.48603. View

17.

Boland G, Butt I, Prasad R, Knox W, Bundred N . COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004; 90(2):423-9. PMC: 2409574. DOI: 10.1038/sj.bjc.6601534. View

18.

Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C . Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62(3):632-5. View

19.

Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H . Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. PMC: 2242660. DOI: 10.1186/bcr1771. View

20.

Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M . Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989; 64(9):1914-21. DOI: 10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g. View